Levafas Diamond

Target species Cattle, sheep Indications for use, specifying the target species For the treatment and control of both gastrointestinal and pulmonary nematode infections, and adult liver fluke infections. Removes most mature Fasciola spp (flukes) present in the bile ducts of the liver. Contraindications Animals must not be treated within a period of 14 days before or after treatment with organophosphorus compounds. Special Warnings for each target species Care should be taken to avoid the following practices because they increase the risk of development of resistance and could ultimately result in ineffective therapy: ∙ Too frequent and repeated use of anthelmintics from the same class, over an extended period of time. ∙ Underdosing, which may be due to underestimation of body weight, misadministration of the product, or lack of calibration of the dosing device (if any) Suspected clinical cases of resistance to anthelmintics should be further investigated using appropriate tests (e.g. Faecal Egg Count Reduction Test). Where the results of the test(s) strongly suggest resistance to a particular anthelmintic, an anthelmintic belonging to another pharmacological class and having a different mode of action should be used. Resistance to levamisole has been reported in Teladorsagia, Cooperia and Trichostrongylus species in sheep in a number of countries, including the EU. There are reports of resistance in Haemonchus in sheep outside the EU. Resistance to levamisole has been reported in Teladorsagia species in cattle in developed countries such as New Zealand. Therefore the use of this product should be based on local (regional, farm) epidemiological information about susceptibility of nematodes and recommendations on how to limit further selection for resistance to anthelmintics. Do not exceed the recommended dosage. Special precautions for use i. Special precautions for use in animals Care should be taken to estimate accurately the liveweight of animals to be treated. Animals should be dosed according to their individual weight, and not dosed as per the heaviest animal in the group, otherwise signs of overdose may occur (see section, Overdose (symptoms, emergency procedures, antidotes), if necessary). It is important that the container is shaken thoroughly before use to ensure that the two active substances are homogeneously resuspended and therefore the animals receive the correct dose. ii. Special precautions to be taken by the person administering the veterinary medicinal product to animals Do not eat, drink or smoke when using this product. Wash splashesfrom eyes and skin immediately. If irritation persists seek medical advice. Remove any contaminated clothing immediately. Wash handsand exposed skin after handling this product, and before meals. Levamisole can cause idiosyncratic reactions and serious blood disorders in a very small number of people. If symptoms such as dizziness, nausea, vomiting or abdominal discomfort are experiencedwhen using this product, or sore mouth/throat or fever occur shortly afterwards, then medical advice should be sought immediately. Adverse reactions (frequency and seriousness) At normal oxyclozanide dose levels, cattle may show slight softening of the faeces with the occasional animal showing increased frequency of defecation and transient inappetence. Rarely, animals may also display signs of ataxia, incoordination, recumbency and depression. Additionally, rarely, sheep may show an allergic reaction such as submandibular oedema, ear flap oedema and swelling of the head. If such a reaction occurs, appropriate treatment should be administered without delay. Such reactions may evolve to a more severe condition (anaphylaxis), which may be life-threatening. The frequency of adverse reactions is defined using the following convention. Use during pregnancy, lactation or lay The product can be safely administered to pregnant or lactating animals. However care should be taken when treating heavily pregnant animals, and animals under stress from adverse weather conditions, poor nutrition, penning, handling etc. Interaction with other medicinal products and other forms of interaction Animals must not be treated within a period of 14 days before or after treatment with organophosphorus compounds.